Annual Reports

 
Quarterly Reports

  • 10-Q (Feb 7, 2011)
  • 10-Q (Nov 5, 2010)
  • 10-Q (Aug 5, 2010)
  • 10-Q (Feb 5, 2010)
  • 10-Q (Nov 6, 2009)
  • 10-Q (Aug 10, 2009)

 
8-K

 
Other

Matrixx Initiatives 10-Q 2007
e10vq
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
Form 10-Q
(Mark One)
     
þ   Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarter ended June 30, 2007
or
     
o   Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from                      to                     
Commission File number 001-31404
Matrixx Initiatives, Inc.
(Name of registrant as specified in its charter)
     
Delaware   87-0482806
(State or other jurisdiction   (I.R.S. Employer
of incorporation or organization)   Identification Number)
4742 N. 24th Street, Suite 455
Phoenix, AZ 85016

(Address of principal executive offices)
(602) 385-8888
(Issuer’s telephone number)
     Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES þ NO o
     Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer” and “large accelerated filer” in Rule 12b-2 of the Exchange Act.
             
 
  Large accelerated filer   Yes o   No þ
 
  Accelerated filer   Yes þ   No o
 
  Non-accelerated filer   Yes o   No þ
Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2). YES o NO þ
There were 10,140,670 shares of the registrant’s common stock, $.001 par value, outstanding as of July 31, 2007.
 
 

 


 

MATRIXX INITIATIVES, INC.
FORM 10-Q
INDEX
                 
            Page
PART I   FINANCIAL INFORMATION        
 
               
 
  Item 1.   Condensed Consolidated Balance Sheets as of June 30, 2007 (Unaudited) and March 31, 2007     1  
 
               
 
      Condensed Consolidated Statements of Operations for the three months ended June 30, 2007 and 2006 (Unaudited)     2  
 
               
 
      Condensed Consolidated Statements of Cash Flows for the three months ended June 30, 2007 and 2006 (Unaudited)     3  
 
               
 
      Notes to Condensed Consolidated Financial Statements (Unaudited)     4  
 
               
 
  Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations     10  
 
               
 
  Item 3.   Quantitative and Qualitative Disclosures About Market Risk     19  
 
               
 
  Item 4.   Controls and Procedures     19  
 
               
PART II   OTHER INFORMATION        
 
               
 
  Item 1.   Legal Proceedings     20  
 
               
 
  Item 1A.   Risk Factors     20  
 
               
 
  Item 4.   Submission of Matters to a Vote of Security Holders     20  
 
               
 
  Item 6.   Exhibits     20  
 
               
SIGNATURES     22  
 EX-10.01
 EX-10.02
 EX-10.03
 EX-10.04
 EX-10.05
 EX-31.1
 EX-31.2
 EX-32.1
 EX-32.2
Unless otherwise indicated in this quarterly report, “Matrixx,” “us,” “we,” “our”, “the Company” and similar terms refer to Matrixx Initiatives, Inc. and its subsidiaries. “Zicam” is a registered trademark of our subsidiary, Zicam, LLC, and the Matrixx name and logo are trademarks of the Company.

2


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
                 
    June 30,   March 31,
    2007   2007
     
ASSETS
               
Current Assets:
               
Cash and cash equivalents
  $ 15,523,861     $ 16,944,189  
Accounts receivable:
               
Trade, net of allowance for doubtful accounts of $189,910 and $429,031
    6,162,435       8,256,929  
Other receivable
    3,797        
Insurance receivable
    107,500       2,200,000  
Inventories
    18,037,942       15,458,928  
Prepaid expenses
    2,093,944       584,771  
Interest receivable
    82,872       84,191  
Income tax receivable
    1,380,277       1,370,277  
Deferred tax asset
    4,157,721       3,361,605  
     
Total Current Assets
    47,550,349       48,260,890  
     
 
               
Property and Equipment, at cost:
               
Office furniture and computer equipment
    1,362,159       1,356,931  
Machine tooling and manufacturing equipment
    5,261,320       5,225,020  
Laboratory furniture and equipment
    356,633       339,343  
Leasehold improvements
    354,744       350,576  
     
 
    7,334,856       7,271,870  
Less accumulated depreciation
    (2,233,339 )     (1,925,598 )
     
 
               
Net Property and Equipment
    5,101,517       5,346,272  
     
 
               
Other Assets:
               
Deposits
    273,172       221,963  
Other assets
    82,770       82,770  
Restricted cash
    500,000       500,000  
Debt issuance costs, net of accumulated amortization of $55,232 and $48,061
          7,171  
Patents, net of accumulated amortization of $478,514 and $446,002
    1,659,603       1,692,115  
Goodwill
    15,039,836       15,039,836  
     
 
               
Total Other Assets
    17,555,381       17,543,855  
     
 
               
Total Assets
  $ 70,207,247     $ 71,151,017  
     
 
               
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
 
               
Current Liabilities:
               
Accounts payable
  $ 3,141,961     $ 2,584,553  
Accrued expenses
    3,133,359       3,162,814  
Sales commissions
    120,844       372,206  
Sales returns and allowances
    1,520,833       2,391,290  
Legal liability
    1,031,000       1,045,000  
     
 
               
Total Current Liabilities
    8,947,997       9,555,863  
     
 
               
Deferred tax liability
    1,228,790       1,160,328  
     
 
               
Total Liabilities
    10,176,787       10,716,191  
 
               
Commitments and Contingencies
               
 
               
Stockholders’ Equity:
               
Preferred stock: $.001 par value, 2,000,000 shares authorized, none issued
           
Common stock: $.001 par value, 30,000,000 shares authorized, 10,120,670 and 10,079,317 shares issued
    10,120       10,079  
Additional paid-in capital
    49,779,904       49,122,216  
Retained earnings
    10,636,740       11,698,835  
     
 
    60,426,764       60,831,130  
Less common stock held in treasury, at cost (53,800 shares)
    (396,304 )     (396,304 )
     
Total Stockholders’ Equity
    60,030,460       60,434,826  
     
Total Liabilities and Stockholders’ Equity
  $ 70,207,247     $ 71,151,017  
     
The accompanying notes are an integral part of these condensed consolidated financial statements.

1


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED JUNE 30, 2007 AND 2006

(Unaudited)
                 
    2007   2006
     
Net sales
  $ 8,573,428     $ 8,206,133  
Cost of sales
    2,835,354       2,404,707  
     
 
               
Gross Profit
    5,738,074       5,801,426  
 
               
Selling, general and administrative expenses
    6,256,215       7,578,412  
Research and development
    1,453,053       1,863,189  
     
 
               
Loss From Operations
    (1,971,194 )     (3,640,175 )
     
 
               
Other Income (Expense):
               
Interest and other income
    246,575       134,808  
Interest expense
           
     
 
               
Total Other Income
    246,575       134,808  
     
 
               
Loss Before Benefit From Income Taxes
    (1,724,619 )     (3,505,367 )
 
               
Benefit from income taxes
    (662,523 )     (1,647,570 )
     
 
               
Net Loss
  $ (1,062,096 )   $ (1,857,797 )
     
 
               
Net Loss Per Share of Common Stock:
               
Basic:
               
Weighted Average Number of Common Shares Outstanding
    9,778,192       9,658,471  
Net Loss Per Share of Common Stock
  $ (0.11 )   $ (0.19 )
 
               
Diluted:
               
Weighted Average Number of Common Shares Outstanding
    9,778,192       9,658,471  
Net Loss Per Share of Common Stock
  $ (0.11 )   $ (0.19 )
The accompanying notes are an integral part of these condensed consolidated financial statements.

2


Table of Contents

MATRIXX INITIATIVES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED JUNE 30, 2007 AND 2006

(Unaudited)
                 
    2007   2006
     
Cash Flows From Operating Activities
               
Net loss
  $ (1,062,096 )   $ (1,857,797 )
Adjustments to reconcile net loss to net cash used in operating activities:
               
Depreciation
    307,741       141,115  
Amortization
    39,683       41,552  
Deferred income taxes
    (727,654 )     (5,636 )
Common stock issued for compensation
    399,027       150,252  
Changes in assets and liabilities:
               
Accounts receivable
    2,094,494       4,860,665  
Insurance receivable
    2,092,500        
Interest and other receivables
    (2,478 )     142,104  
Income tax receivable
    (10,000 )     (2,225,547 )
Inventories
    (2,579,014 )     (4,351,764 )
Prepaid expenses and other
    (1,509,173 )     (1,057,714 )
Accounts payable
    557,408       1,543,940  
Accrued expenses
    (280,817 )     (3,378,673 )
Legal liability
    (14,000 )     (35,000 )
Sales returns and allowances
    (870,457 )     (511,989 )
     
 
               
Net Cash Used In Operating Activities
    (1,564,836 )     (6,544,492 )
     
 
               
Cash Flows From Investing Activities
               
Capital expenditures
    (62,986 )     (506,772 )
Deposits and other
    (51,209 )     (1,518,420 )
Restricted cash
          4,500,000  
     
 
               
Net Cash (Used) Provided By Investing Activities
    (114,195 )     2,474,808  
     
 
               
Cash Flows From Financing Activities:
               
Debt issuance costs
          (6,442 )
Issuance of common stock
    258,703       292,695  
     
 
               
Net Cash Provided By Financing Activities
    258,703       286,253  
     
 
               
Net Decrease in Cash and Cash Equivalents
    (1,420,328 )     (3,783,431 )
 
               
Cash and Cash Equivalents at Beginning of Period
    16,944,189       11,401,441  
     
 
               
Cash and Cash Equivalents at End of Period
  $ 15,523,861     $ 7,618,010  
     
 
               
Supplemental Disclosure of Cash Flow Information:
               
Cash paid during the period for:
               
Interest
  $     $  
Income taxes
          683,327  
The accompanying notes are an integral part of these condensed consolidated financial statements.

3


Table of Contents

MATRIXX INITIATIVES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
  1.   Financial Statements
     The accompanying condensed consolidated balance sheet as of March 31, 2007, which has been derived from audited consolidated financial statements, and the unaudited interim condensed consolidated financial statements of Matrixx Initiatives, Inc. as of and for the three months ended June 30, 2007 have been prepared in accordance with the rules prescribed for filing condensed interim financial statements and, accordingly, do not include all disclosures that may be necessary for complete financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The disclosures presented are sufficient, in management’s opinion, to make the interim information presented not misleading. All adjustments consisting of normal recurring adjustments that are necessary so as to make the interim information not misleading, have been made. All references made in this Report to “Note” or “Notes” refer to these Notes to the Condensed Consolidated Financial Statements. Results of operations for the three months ended June 30, 2007 are not necessarily indicative of results of operations that may be expected for the fiscal year ending March 31, 2008. The products we market are seasonal in nature, and sales at retail generally increase as the incidence of colds and flu rises. We record sales when products are shipped from our warehouse facilities. Due to the seasonal nature of the Company’s business, fiscal first quarter (ended June 30) sales generally account for less than 10% of annual sales and the Company has historically recorded a loss in that quarter. During the July through September quarter, the Company usually realizes increased sales volume as retailers stock our products and order displays to prepare for the cough and cold season, which usually runs from October through March. Retail consumption of our products is highest during the cough and cold season. It is recommended that this financial information be read in conjunction with the complete financial statements included in Matrixx’s Transition Report on Form 10-KT for the transition period ended March 31, 2007 previously filed with the Securities and Exchange Commission.
  2.   Stock-Based Compensation
     Effective January 1, 2006, the Company adopted Statement of Financial Accounting Standards (“SFAS”) No. 123R (Revised 2004), Share-Based Payment, which revises SFAS No. 123, Accounting for Stock-Based Compensation, and supersedes APB Opinion No. 25, Accounting for Stock Issued to Employees. SFAS No. 123R requires the Company to measure the cost of services received in exchange for equity instruments based on the grant-date fair value of the award and that cost will be recognized to expense over the requisite service or vesting period. SFAS No. 123R allows for the use of the Black-Scholes or a lattice option-pricing model to value such equity instruments. The Company uses the Black-Scholes option-pricing model in valuing such equity instruments. Upon adoption, the Company transitioned to SFAS No. 123R using the Modified Prospective Application (MPA) transition method, whereby compensation cost is recognized for new awards and awards modified after the effective date, and to that portion of outstanding awards for which part or all of the requisite service will be rendered on or after the effective date. As a result of applying SFAS No. 123R, the Company recognized pre-tax charges of $12,139 as compensation expense, approximately $7,500 after tax, in the quarter ended June 30, 2007, compared to pre-tax charges of $49,920, approximately $30,000 after tax, for the quarter ended June 30, 2006, related to unvested options as of January 1, 2006, and there was an immaterial impact to earnings per share. The Company expects to recognize additional pre-tax charges of $4,000 (in July 2007) in association with the remaining non-vested stock options. These charges will not affect the Company’s cash position. The Company anticipates future equity compensation will be in the form of restricted stock instead of options.
     The fair value for options was estimated at the date of grant using the Black-Scholes option pricing model with the following assumptions for the years ended December 31, 2005 and 2004.
                 
    2005   2004
Risk-free interest rate
    3.66 %     3.25 %
Expected life
  5.00  years   4.95  years
Expected volatility
    61.40 %     66.44 %
Expected dividend yield
    0 %     0 %

4


Table of Contents

MATRIXX INITIATIVES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
The Company has granted restricted stock to directors, officers, and management employees as part of its overall compensation plan. Compensation expense is based on the fair value of the shares on the date of their grant (as determined by the closing stock price on the grant date), and is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense recognized in the quarter ended June 30, 2007, for restricted stock awards previously granted, was approximately $150,000, or $92,000 after tax, compared to approximately $63,200, after tax, for the quarter ended June 30, 2006. Also, during the quarter ended June 30, 2007, 910 shares of restricted stock were issued to two directors, in lieu of cash, under the Directors Restricted Stock Purchase Program for fiscal first quarter director compensation. For the three months ended June 30, 2007, 21,667 options were exercised at a weighted average exercise price of $11.94. No options were granted during the quarters ended June 30, 2007 or 2006.
  3.   Basic and Diluted Loss Per Share
     The Company follows the provisions of SFAS No. 128, “Earnings Per Share,” which specifies the method of computation, presentation and disclosure of earnings per share. SFAS No. 128 requires the presentation of two earnings per share amounts, basic and diluted. Basic earnings per share is calculated using the average number of common shares outstanding. Diluted earnings per share is computed on the basis of the average number of common shares outstanding plus the effect of dilutive securities. The Company’s stock options, warrants and restricted stock are included using the “treasury stock” method.
     The table below summarizes the elements included in the calculation of basic and diluted net loss per common share for the three months ended June 30, 2007 and 2006. Options, warrants and other incremental shares to purchase 593,901 and 785,684 shares of common stock for the three months ended June 30, 2007 and 2006, respectively, were not included in the computation of diluted loss per share because their effect would be anti-dilutive due to the loss reported in the quarters.
                 
    Three Months Ended  
    June 30,  
    2007     2006  
Net loss applicable to common shareholders
  $ (1,062,096 )   $ (1,857,797 )
 
           
Weighted average common shares outstanding – Basic
    9,778,192       9,658,471  
Dilutive Securities:
               
Options
           
Restricted Stock
           
 
           
Weighted average common shares outstanding — Diluted
    9,778,192       9,658,471  
 
           
 
               
Net loss per common share:
               
Basic
  $ (0.11 )   $ (0.19 )
Diluted
  $ (0.11 )   $ (0.19 )

5


Table of Contents

MATRIXX INITIATIVES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)
  4.   Inventories
     Inventories are stated at the lower of cost or market. The Company uses first-in, first-out (FIFO) to value inventory. Inventories consisted of the following at June 30, 2007 and March 31, 2007:
                 
    June 30,     March 31,  
    2007     2007  
Raw materials and packaging
  $ 4,179,717     $ 4,391,903  
Finished goods
    13,858,225       11,067,025  
 
           
Total
  $ 18,037,942     $ 15,458,928  
 
           
     The increase in finished goods inventory relates to our expectations of higher sales in the upcoming cold season. We generally employ purchasing practices to meet future sales expectations and our manufacturers schedule production in order to ensure adequate supply during our highest sales periods.
5.   Recently Issued Accounting Standards
     See Note 2 for a discussion of stock-based compensation accounting standards that became effective January 1, 2006.
     In July 2006, the FASB issued Interpretation No. 48, “Accounting for Uncertainty in Income Taxes”, effective for fiscal years beginning after December 15, 2006. The interpretation applies to tax positions within the scope of SFAS No. 109, Accounting for Income Taxes. Interpretation 48 is a two-step process for recognition and evaluation of uncertain tax positions. It requires the Company to assess whether a tax position is “more-likely-than-not” to be sustained based on its technical merits and then to determine the amount of the tax position to be recognized in the financial statements. The Company implemented Interpretation No. 48 beginning January 1, 2007. Adoption of FIN 48 did not have a material impact on our earnings, financial position, or cash flows. As of June 30, 2007, the Company believes that all of its tax positions are more likely than not to be sustained based on their technical merits.
     In September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements” (SFAS 157), effective for fiscal years beginning after November 15, 2007. SFAS 157 provides guidance on how to measure assets and liabilities that use fair value, and expands disclosure about fair value measurement. SFAS 157 will apply whenever another GAAP standard requires (or permits) assets or liabilities to be measured at fair value but does not expand the use of fair value to any new circumstances. The Company will adopt SFAS 157 April 1, 2008. Adoption of SFAS 157 is not expected to have a material impact on our earnings, financial position, or cash flows.
     In September 2006, the U.S. Securities and Exchange Commission issued Staff Accounting Bulletin (“SAB”) No. 108, “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements.” SAB 108 provides guidance on the consideration of the effects of prior year misstatements in quantifying current year misstatements in determining whether the current year’s financial statements are materially misstated. SAB No. 108 is effective for fiscal years ending after November 15, 2006. The Company has adopted SAB No. 108 as of December 31, 2006 and its adoption did not have an impact on the Company’s consolidated financial statements.

6


Table of Contents

     In February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities: Including an amendment of FASB Statement No. 115” (SFAS 159). SFAS 159 permits entities to measure many financial instruments and certain other items at fair value with changes in fair value reported in earnings. The FASB issued SFAS 159 to mitigate earnings volatility that arises when financial assets and liabilities are measured differently, and to expand the use of fair value measurement for financial instruments. SFAS 159 is effective as of the beginning of the first fiscal year that begins after November 15, 2007. We will adopt SFAS 159 beginning April 1, 2008. Adoption of SFAS 159 is not expected to have a material impact on our earnings, financial position, or cash flows.
6.   Insurance Program
     In April 2004, we established a fully-funded deductible insurance program through a product liability insurance carrier. Under the program, we agreed to reimburse our insurer for its claims administration expenses and for amounts paid out by it in settlement of product liability claims filed after the initial date of the program and which are not covered by insurance programs from prior years. The terms of the program required us to maintain an irrevocable, evergreen letter of credit issued by a bank or other financial institution to secure our reimbursement obligations to our insurer. We had a $5.0 million letter of credit with Comerica Bank and had reserved an equal amount of cash to secure repayments of amounts that became due under the letter of credit. The settlement of the consolidated Arizona litigation in January of 2006 exhausted this policy. In April 2006, we replaced the self-funded insurance program with a limited traditional insurance program. This new insurance program does not cover lawsuits existing prior to April 2006, and only applies to any new claims made after the new policy was effective. The new policy requires a $500,000 letter of credit instead of a $5.0 million letter of credit, as was required under the previous policy. The $5.0 million previously classified as Restricted Cash on the balance sheet was released in April 2006, with the commencement of the new insurance program and a new letter of credit for $500,000 was issued with an equal amount of cash reserved, which is shown as restricted cash on the June 30, 2007 and March 31, 2007 condensed consolidated balance sheets. We expect future reimbursements from our insurance carriers for legal expenses incurred in fiscal 2008 or any future periods to be minimal.
7.   Legal Proceedings
 
    Litigation
     The Company is involved in various product liability claims and other legal proceedings. The Company’s legal expense for defense of these lawsuits continues to have a significant impact on the results of operations as the Company defends itself against the various claims.
     Among the principal matters pending to which the Company is a party are the following:
Product Liability Matters
     General. Numerous lawsuits have been filed against us alleging that our Zicam Cold Remedy nasal gel product has caused the permanent loss or diminishment of the sense of smell or smell and taste. As discussed in greater detail below, we believe these allegations are unfounded. The Company is incurring significant legal expense for defense of these lawsuits. For the three months ended June 30, 2007, litigation expense was approximately $830,000 ($930,000 reduced by expected reimbursement of approximately $100,000 from our insurance carriers for litigation defense expense incurred in the period). For the quarter ended June 30, 2006, litigation expense was approximately $2.1 million (no insurance reimbursement was recorded in the quarter ended June 30, 2006). We expect future reimbursements from our insurance carriers for legal expenses incurred in fiscal 2008 or any future periods to be minimal.
     From March 31, 2007 through July 31, 2007, seven new product liability cases were filed against the Company and ten product liability cases were dismissed or are pending dismissal either as a result of successful Company motions or through the settlement of cases for immaterial amounts. The following chart discloses the number of outstanding product liability cases (excluding those cases that have been settled but not yet dismissed) and associated plaintiffs at the indicated dates:
                                 
    December 31, 2005   December 31, 2006   March 31, 2007   July 31, 2007
Number of Pending Lawsuits
    50       25       28       25  
Number of Plaintiffs
    427       36       40       36  

7


Table of Contents

Three of the pending lawsuits were filed as class action lawsuits covering named and unnamed plaintiffs. Various defendants in the lawsuits, including manufacturers and retailers, have received indemnification or other recovery from us for damages related to the lawsuits.
     Settlement of Arizona Consolidated Litigation. On January 19, 2006, we entered into an agreement to settle claims made by approximately 90% of the plaintiffs (approximately 340 individuals) in all of the Zicam Cold Remedy product liability lawsuits pending against the Company at that time. This settlement related to the Arizona consolidated litigation, In Re Consolidated Zicam Product Liability Cases, Superior Court of Arizona (Maricopa County). The settlement documents acknowledge that Matrixx has denied and continues to deny any liability to the plaintiffs. Those plaintiffs who were eligible and elected to participate in the settlement program dismissed their claims with prejudice and provided written releases of their claims against the Company in return for their participation. Of the plaintiffs who did not participate in the settlement program, all have dismissed their claims as of July 31, 2007. Matrixx paid $11.9 million to fund awards to be made under the settlement program. In addition, Matrixx paid $100,000 to cover the administration of the settlement program by plaintiffs’ counsel. The Company recognized a charge of approximately $4.3 million (after tax) in the fourth quarter of 2005 to cover the portion of the settlement program costs not expected to be covered by insurance.
     Cases Dismissed Since March 31, 2007 (Federal Courts). The following federal court cases against the Company were dismissed since March 31, 2007:
             
Date Filed   United States District Court   Named Plaintiff   Date Dismissed
June 15, 2004
  Northern District of Alabama, Middle Division   Wyatt   July 19, 2007
 
           
November 1, 2005
  Northern District of Georgia   Abernathy   April 16, 2007
 
           
November 4, 2005
  Eastern District of Tennessee, Chattanooga Division   Russell   May 21, 2007
 
           
December 21, 2005
  Eastern District of Michigan   Salden   May 17, 2007
 
           
April 13, 2006
  Southern District of Ohio   Rife   June 25, 2007
 
           
October 6, 2006
  Central District of California   Navas   April 26, 2007
 
           
November 2, 2006
  Northern District of Ohio, Western Division   Taylor   June 26, 2007
     Federal law and the law of many states requires that the testimony of a scientific or medical expert witness be reliable and based on valid scientific data and analysis before it can be allowed into evidence. To date, the Company has submitted motions in eight federal lawsuits against the Company challenging the reliability and admissibility of the testimony of expert witnesses who claim that Zicam is capable of causing or has caused smell and taste loss. To date, the courts have ruled on seven of the eight motions. Each court has ruled that the testimony of the experts lacks reliability and a sufficient scientific basis for admission into evidence. The seven cases in which orders have been granted are: Hans, et al. vs. Matrixx Initiatives, Inc., et al. (United States District Court for the Western District of Kentucky); Salden vs. Matrixx Initiatives, Inc., et al. (United States District Court for the Eastern District of Michigan); Sutherland vs. Matrixx Initiatives, Inc., et al. (United States District Court for the Northern District of Alabama); Benkwith vs. Matrixx Initiatives, Inc., et al. (United States District Court for the Middle District of Alabama); O’Hanlon vs. Matrixx Initiatives, Inc., et al. (United States District Court for the Central District of California); Hilton vs. Matrixx Initiatives, Inc., et al. (United States District Court for the Northern District of Texas); and Wyatt vs. Matrixx Initiatives, Inc., et al. (United States District Court for the Northern District of Alabama). In Sutherland, Benkwith, O’Hanlon, and Hilton, the relevant court dismissed the case simultaneously with its ruling to exclude the expert testimony; in Hans a motion for dismissal is pending. In O’Hanlon, the plaintiffs have filed an appeal.
     Cases Dismissed Since March 31, 2007 (State Courts). The following state court cases against the Company were dismissed since March 31, 2007:
             
Date Filed   Court   Named Plaintiff   Date Dismissed
March 11, 2004
  Maricopa County, Arizona   Abramsen   May 31, 2007
 
           
June 7, 2006
  Superior Court of New Jersey, Morris County   Stracco   June 20, 2007
 
           
June 21, 2006
  County of Bernalillo, State of New Mexico   Otero   April 12, 2007

8


Table of Contents

     Pending Cases as of July 31, 2007 (Federal Courts). Eleven federal court cases remain pending against the Company, covering approximately 19 plaintiffs. This includes the following new federal court cases that have not been previously disclosed:
         
Date Filed   United States District Court   Named Plaintiff
May 30, 2007
  Northern District of Illinois   McGill
 
       
June 6, 2007
  Eastern District of Tennessee, Chattanooga Division   Newman
     Pending Cases as of July 31, 2007 (State Courts). Fourteen state court cases remain pending against the Company, covering approximately 17 plaintiffs. This includes the following new state court cases that have not been previously disclosed:
         
Date Filed   Court   Named Plaintiff
May 4, 2007
  State of Arizona, County of Maricopa   Brierly
 
       
July 12, 2007
  Superior Court of Chelan County, Washington   Ballew
     Potential Claimants. The Company has been advised that certain plaintiffs’ attorneys collectively represent approximately 450 additional potential claimants for whom they have not yet filed lawsuits. The Company is in the process of determining the number of potential claimants, the nature or basis of their purported claims, and when or if the potential claimants will ultimately file one or more lawsuits against the Company.
     Plaintiffs’ law firms may continue to solicit potential claimants and, as a result, additional lawsuits may be filed against us. We cannot predict the outcome of the litigation but we will defend ourselves vigorously. If any liability were to result from one or more of these or future lawsuits, we believe our financial results could be materially impacted. Our financial results also could be materially impacted by the adverse publicity that may result from the lawsuits.
     Company’s Position Regarding the Allegations. Matrixx continues to believe that Zicam Cold Remedy intranasal gel does not cause loss of smell and that claims to the contrary are scientifically unfounded and misleading. The Company believes that upper respiratory infections and nasal and sinus disease are the causes of the smell dysfunctions reported by some consumers. One of the most common causes of smell disorders is the cold itself, the very condition the product is used to treat. Other causes are sinusitis and rhinitis, conditions which are sometimes present when the product is used. The Company’s position is supported by cumulative science, and it has now been confirmed by a multi-disciplinary panel of scientists.
     Scientific Advisory Board. We convened a Scientific Advisory Board to review claims that use of Zicam Cold Remedy intranasal gel spray can lead to the diminishment or loss of sense of smell. The Advisory Board is comprised of medical doctors and researchers who are independent of the Company. Matrixx provided honorariums for members’ attendance at meetings, travel expenses, and funded grants to design and perform research studies investigating the contention that Zicam Cold Remedy zinc gluconate nasal gel is associated with disorders of smell.
     In February 2004, the Advisory Board initially reviewed the claims and found that the allegation was largely anecdotal and based on unsupported analogies and generally appeared to lack scientific merit. However, in an effort to further explore the issues, the Advisory Board and the Company designed and had performed studies to (1) better assess the causes of smell loss and the rate at which smell loss occurs; (2) determine whether any substantial amount of the nasal gel interacts with the smell tissue located at the very top portion of the nasal cavity; and (3) evaluate through animal experiments how much Zicam would be needed to have any effect on smell function.
     In 2004 and 2005, the studies designed by the Advisory Board were conducted and completed. After reviewing the data, the Advisory Board unanimously concluded that the cumulative scientific evidence failed to support the suggestion that Zicam use is associated with impairment of the senses of smell and taste. Rather, the evidence confirms that the major causes of smell loss are upper respiratory infection and nasal and sinus disease, all of which are ever-present in the population of Zicam users. None of the Zicam gel approaches the smell tissue when Zicam is used as directed, and there is only scant and questionable evidence that even trace amounts can reach the upper nasal cavity when the product is egregiously misused.

9


Table of Contents

     Insurance. We submit lawsuits to our insurance carriers when applicable. In April 2004, we established a fully-funded deductible insurance program through a product liability insurance carrier. The settlement of the consolidated Arizona litigation exhausted this insurance program. In April 2006, we replaced the self-funded program with a limited traditional insurance program. This new insurance program does not cover previously existing lawsuits and only applies to any new claims made after it became effective (see Note 6 to the Condensed Consolidated Financial Statements). We expect future reimbursements from our insurance carriers for legal expenses incurred in fiscal 2008 or any future periods to be minimal.
Litigation Reserves
     As of December 31, 2005, the Company established a reserve of $1.3 million for any future payment of settlement or losses related to the cold remedy litigation. This reserve was based on certain assumptions, some of which are described below, and was the amount, excluding defense costs, the Company believed it could reasonably estimate would be spent to resolve the remaining cases that have been filed. Some of the significant factors that were considered in the establishment of the reserve were as follows: the actual costs incurred by the Company up to that time in resolving several claims; the development of the Company’s legal defense strategy and structure in light of the Arizona settlement; and the number of cases that remain pending against the Company. There are events, such as the dismissal of any cases, the filing of new lawsuits, threatened claims, the outcome of a trial, or rulings on pending evidentiary motions, that may have an impact on the Company’s conclusions as to the adequacy of the reserves for the pending product liability lawsuits. Litigation is inherently unpredictable and excessive verdicts do occur. Although we believe we have substantial defenses in these matters, we could in the future incur judgments or enter into settlements of claims that could have a material adverse effect on our results of operations in any particular period. The Company regularly reviews this reserve and may make adjustments based on the number of pending, settled, and threatened cases, as well as continuing legal defense strategy. As of June 30, 2007 the reserve was approximately $1.0 million. The Company will continue to review the adequacy of the associated reserves on a quarterly basis.
   Securities Litigation Matters
     Two class action lawsuits were filed in April and May 2004 against the Company, our President and Chief Executive Officer, Carl J. Johnson, and our Executive Vice President and Chief Financial Officer, William J. Hemelt, alleging violations of federal securities laws. On January 18, 2005, the cases were consolidated and the court appointed James V. Sircusano as lead plaintiff. The amended complaint also includes our Vice President of Research and Development, Timothy L. Clarot, as a defendant and was filed March 4, 2005. The consolidated case is Sircusano, et al. vs. Matrixx Initiatives, Inc., et al., in the United States District Court, District of Arizona, Case No. CV04-0886 PHX DKD. Among other things, the lawsuit alleges that between October 2003 and February 2004, we made materially false and misleading statements regarding our Zicam Cold Remedy product, including failing to adequately disclose to the public the details of allegations that our products caused damage to the sense of smell and of certain of the product liability lawsuits described above. We filed a motion to dismiss this lawsuit and, on March 8, 2006, the Company received an Order dated December 15, 2005 granting the motion to dismiss the case, without prejudice. On April 3, 2006, the plaintiff appealed the Order to the United States District Court of Appeals, Ninth Circuit, Case No. 2:04-CV-886. In accordance with and subject to the provisions of the Company’s Certificate of Incorporation, Messrs. Johnson, Hemelt, and Clarot will be indemnified by the Company for their expenses incurred in defending these lawsuits and for any other losses which they may suffer as a result of these lawsuits. The Company has submitted this matter to its insurance carriers and may incur charges up to the deductible amount of $1 million. If any liability were to result from this lawsuit that is not covered by insurance, we believe our financial results could be materially impacted.
Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations
Overview
     Through our 100%-owned subsidiary, Zicam LLC, the Company develops, produces, markets and sells innovative, over-the-counter (OTC) healthcare products with an emphasis on those that utilize unique, novel and/or proprietary delivery systems that provide consumers with “Better Ways to Get Better®”. The Company currently markets its products within the $4.0 billion overall cough and cold category at retail. Our Zicam products are sold in the cold (nasal delivery and oral delivery products), allergy/sinus (nasal delivery), cough (cough spray and RapidMelt tablet delivery), and multi-symptom relief (oral delivery) market groups of the overall cough and cold

10


Table of Contents

category. Our Nasal Comfort products are generally sold within the space allocated for allergy and sinus products at retail. We expect that our mix of products sold will change due to seasonality and varying growth rates within the market groups. Our products are currently available at all of the major food, drug, and mass merchant retailers.
     Because of the extreme seasonality of our business, our Board of Directors approved a change in our fiscal year in order to better align our operations and financial results with the entire cold season (our previous fiscal year ended in the middle of the cold season). Due to the change in our fiscal year, the three months ended March 31, 2007 are reported as a transition period. Our new fiscal year began April 1, 2007 and ends March 31, 2008. Most of the products we market are seasonal in nature, and sales at retail generally increase as the incidence of colds and flu rises. We record sales when products are shipped from our warehouse facilities. During the July through September quarter, the Company usually realizes increased sales volume as retailers stock our products and order displays to prepare for the upcoming cough and cold season. Additional sales (re-orders) to retailers are highly dependent upon the incidence of illness within the population. Retail sales of our products are highest during the cough and cold season, which usually runs from October through March. The Company begins extensive advertising campaigns to coincide with the cough and cold season and generally realizes higher advertising expense in the October through March time periods.
     Certain information is set forth below for our operations, expressed in thousands of dollars and as a percentage of net sales, for the periods indicated:
                                 
    3 Months Ended June 30,
$000s   2007   % NS   2006   % NS
Net Sales
  $ 8,573       100 %   $ 8,206       100 %
 
                               
Marketing
  $ 2,143       25 %   $ 1,792       22 %
Sales
  $ 742       9 %   $ 446       5 %
General & Administrative
  $ 2,542       29 %   $ 3,223       39 %
Product Liability Litigation
  $ 829       10 %   $ 2,117       26 %
 
Total Selling, General and Administrative Expenses
  $ 6,256       73 %   $ 7,578       92 %
 
 
                               
 
Research & Development
  $ 1,453       17 %   $ 1,863       23 %
 
     Net sales for the quarter ended June 30, 2007 increased 4% to approximately $8.6 million compared to approximately $8.2 million for the quarter ended June 30, 2006. The growth in sales is primarily due to an increase in allergy/sinus and multi-symptom products, compared to the quarter ended June 30, 2006. We expect that our mix of products sold will change due to seasonality and varying growth rates within the market groups.
     Net loss for the quarter ended June 30, 2007 was approximately $(1.1) million, compared to a net loss of $(1.9) million in the quarter ended June 30, 2006. The decreased net loss is due to increased net sales offset by lower gross margins, a reduction in general and administrative expenses, and a decrease in product liability litigation expense. During the quarter ended June 30, 2007, the Company recorded approximately $830,000 for litigation expense related to the product liability lawsuits (which reflects approximately $100,000 in expected insurance reimbursements), compared to approximately $2.1 million for litigation expense during the quarter ended June 30, 2006 (no insurance reimbursement was recorded in the quarter ended June 30, 2006). In addition, during our quarterly review of balance sheet allowances, we determined that our allowance for bad debt exceeded the amount of loss that would be likely and we reduced the allowance amount by approximately $250,000. This reduction is reflected in selling, general and administrative expenses.
     We expect net income (loss) in future periods to be significantly affected by the level of sales, the timing and amount of our advertising, research and development expenses, and the timing and amount of expenses incurred in defense of product liability litigation matters. Expenditures for advertising and research and development will vary by quarter throughout the year and could be significantly different in future periods than the amounts incurred in the same period in earlier years. We expect that advertising expenses will be highest during the cold season (third and fourth fiscal quarters). We anticipate quarterly earnings will continue to vary along with the seasonality of sales and the level of marketing and research and development expense.
     The Company’s management reviews several key indicators in evaluating the Company’s overall performance:

11


Table of Contents

  1)   We compare our year-to-date sales and net income performance against our stated annual goal for each. For fiscal 2008, our goal is to grow sales 5% to 15% above the $97.6 million recorded for the trailing twelve months ended March 31, 2007 and to increase net income to the range of $9.3 million to $10.8 million, compared to $6.5 million for the twelve months ended March 31, 2007. For the three months ended June 30, 2007, the Company expected net sales would surpass the level achieved during the comparable period in the prior year and the seasonal net loss would be reduced. For the three months ended June 30, 2007, we realized net sales growth of 4% and net loss was reduced approximately $795,000 from the net loss recorded for the quarter ended June 30, 2006.
 
  2)   We monitor our share of the cough and cold market. For the 12 weeks ended June 17, 2007, retail sales of our products (as measured by three outlet syndicated scanner data, not including our largest customer, Wal-Mart) increased approximately 16% over the comparable period in the previous year, while the entire cough and cold category increased approximately 5% over the same period.
 
  3)   We measure our ability to maintain strong gross margins on our products. During the three months ended June 30, 2007, we realized an average gross margin of 67%, which is below our goal of 70%, and below the average gross margin of 71% realized in the quarter ended June 30, 2006 (gross margins on our existing products vary between 50% and 80%). Average gross margins were negatively impacted by the mix of products sold as well as an increase in promotional spending, which reduced the average selling price per unit sold. We are beginning to realize margin improvement related to our improved swab and multi-symptom spoon products.
 
  4)   We evaluate our operating performance by reviewing, over time, our ability to decrease administrative and general costs as a percentage of net sales. For the three months ended June 30, 2007, our selling, general and administrative expenses were approximately 73% of our net sales compared to 92% in the three months ended June 30, 2006.
 
  5)   We review the distribution and mix of our products by key national retailers. Our ten largest retail customers account for a substantial majority of our annual sales and we encourage our largest customers to carry a mix of our highest selling products. Retailers generally reset their cough and cold sections during the third calendar quarter of each year, at which time we are informed of any changes that will occur for the upcoming cough and cold season. We encourage retailers to swap out discontinued items for faster selling products and we expect our largest customers to add some of our new products (Zicam Multi-symptom bottles and Zicam Sinus RapidMelts) for the upcoming cold season.
Critical Accounting Policies and Estimates
     Our condensed consolidated financial statements and accompanying notes have been prepared in accordance with GAAP applied on a consistent basis. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.
     We regularly evaluate the accounting policies and estimates that we use to prepare our consolidated financial statements. In general, management’s estimates are based on historical experience, on information from third party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management.
     We believe that our critical accounting policies and estimates include the accounting for intangible assets and goodwill, accounting for income taxes, revenue recognition, accounting for sales returns and allowances associated with our products, accounting for sales discounts and promotional programs, and accounting for legal contingencies.
     Intangible Assets and Goodwill: We recorded approximately $15.0 million in goodwill in connection with the 40% Zicam, LLC interest acquired from Zensano, Inc. in December 2001. Under SFAS No. 142, goodwill must be tested when a triggering event occurs or at least annually to identify a potential impairment and the amount of any impairment loss. Factors that could affect this analysis would be significant loss of market share, a general decline in Zicam product sales, higher than expected increases in expenses and various other matters. Any change in key assumptions about the business or prospects of Zicam, LLC, or any change in market conditions or other externalities affecting Zicam, LLC, could result in an impairment charge, and such a charge could have a material adverse effect on our financial condition and results of operations. Our annual valuation of goodwill was completed

12


Table of Contents

in September 2006 and no impairment was identified. No triggering events have occurred subsequent to the valuation performed in the third quarter of calendar 2006.
     Income Taxes: In accordance with SFAS No. 109, “Accounting for Income Taxes,” we record income tax expense based on our estimated effective income tax rate for the year and will continue to do so in future periods. In 2005, we fully utilized the tax loss carryforward from prior years. In fiscal 2006 and the three months ended March 31, 2007, we recognized a tax benefit related to the charitable donation of products. At June 30, 2007 we had a $4.2 million tax loss carryforward (expiring in 2026) that we expect to fully utilize in the current fiscal year (April 1, 2007 through March 31, 2008). See Note 5 to the Condensed Consolidated Financial Statements for further information regarding taxes.
     Revenue Recognition: The Company recognizes revenue from product sales when earned, that is, when the risks and rewards of ownership have transferred to the customer, which is considered to have occurred upon shipment of the finished product. Sales incentives, promotional allowances, and returns are estimated and recognized at the date of shipment based upon historical activity and current agreements with customers. The Company evaluates these estimates on a monthly basis and revises them as necessary.
     Customer Sales Returns and Allowances: The estimate for product returns reflects our historical experience of sales to retailers and is reviewed regularly to ensure that it reflects potential product returns. Prior to July 2006, we recorded a returns provision of 3% for products in distribution over a year and 7% for new items. We regularly review the similarities and differences of the new products relative to products for which we now have several years of product return experience. In July 2006, we adjusted our returns provision to 3.5% of gross sales for all of our products, including the new items that began shipping in the third quarter of 2006. Additionally, during calendar 2006, we recorded a $2.5 million adjustment to our returns provision to account for increased returns of Nasal Comfort and discontinued products from a large customer. We will continue to review the return provision at least quarterly and adjust the reserve amounts as actual product return experience continues to develop. Should the actual level of product returns vary significantly from our estimates, our operating and financial results would be materially affected.
     Accounts Receivable and Allowance for Doubtful Accounts: The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. The allowance is reviewed regularly to ensure that it reflects the amount of the Company’s probable credit losses. During the quarter ended June 30, 2007, the Company reviewed the allowance and elected to reduce its accrual rate from 0.10% of gross sales to 0.02% of gross sales, effective April 1, 2007. In addition, during the quarter ended June 30, 2007, the Company reduced its allowance by approximately $250,000, which has been reflected in general and administrative expense in the accompanying statement of operations.
     Insurance Reimbursements: During the quarter ended June 30, 2007, we recorded approximately $100,000 in expected reimbursement from our insurance carriers. The expected reimbursement relates to product liability litigation defense costs. We believe the amounts are reasonable based on the terms of the respective policies and the costs incurred to date. We expect future reimbursements from our insurance carriers for legal expenses incurred in fiscal 2008 or any future periods to be minimal. See Note 6 to the Condensed Consolidated Financial Statements for additional information regarding our insurance program.
     Legal Contingencies: We are subject to lawsuits, investigations and claims arising out of the normal conduct of our business. See Note 7 to the Condensed Consolidated Financial Statements for information regarding our pending and threatened litigation and our reserves for product liability litigation. While we are vigorously defending ourself in these proceedings, the outcome of these and any other proceedings that may arise cannot be predicted with certainty. The Company follows the guidance of SFAS 5, “Accounting for Contingencies”, which states the Company is required to accrue a contingent loss when the loss is deemed probable and reasonably estimable.
Results of Operations for the Three Months Ended June 30, 2007 Compared to the Three Months Ended June 30, 2006
     Certain information is set forth below for our operations expressed in dollars and as a percentage of net sales for the periods indicated:

13


Table of Contents

                                 
    Three Months Ended June 30,  
    2007     2006  
Net sales
  $ 8,573,428       100 %   $ 8,206,133       100 %
Cost of sales
    2,835,354       33       2,404,707       29  
 
                       
Gross profit
    5,738,074       67       5,801,426       71  
Selling, general and administrative
    6,256,215       73       7,578,412       92  
Research & development
    1,453,053       17       1,863,189       23  
 
                       
Loss from operations
    (1,971,194 )     (23 )     (3,640,175 )     (44 )
Interest and other income
    246,575       3       134,808       2  
Interest expense
    0             0        
 
                       
Loss before income taxes
    (1,724,619 )     (20 )     (3,505,367 )     (43 )
Benefit from income taxes
    (662,523 )     8       (1,647,570 )     20  
 
                       
Net Loss
  $ (1,062,096 )     (12 )%   $ (1,857,797 )     (23 )%
 
                       
Net Sales
     Net sales for the three months ended June 30, 2007 were $8.6 million, or 4% above net sales of $8.2 million for the quarter ended June 30, 2006. The increase in sales is primarily related to an 8% increase in allergy/sinus product sales and a 92% increase in multi-symptom product sales, which were partially offset by a 3% decrease in cough sales and an increase in customer fees and early pay discounts. During the quarter ended June 30, 2007, our list price for products did not change; however, an increase in promotional support contributed to a lower average net sales price per unit sold.
Cost of Sales
     For the quarter ended June 30, 2007, our cost of sales increased approximately $430,000, or 18% over the cost of sales for the quarter ended June 30, 2006. The increase was primarily due to the increased number of units sold as well as the mix of products sold. Particularly affecting the increased cost of goods sold was the increased number of Cold Remedy RapidMelt® products sold compared to nasal products, and the cost of our Cough Max spray versus several of our other cough products. During the quarter ended June 30, 2007, we began to realize cost savings associated with the improved and lower cost Cold Remedy Swab products and multi-symptom spoon relief items.
Gross Profit
     Gross profit for the three months ended June 30, 2007 was approximately $5.7 million, compared to gross profit of approximately $5.8 million for the quarter ended June 30, 2006. The slightly lower gross profit is due to the lower average gross margin percentage achieved during the quarter. The gross margins for the quarter ended June 30, 2007 decreased to 67% from 71% in the comparable quarter of 2006. The decrease in gross margins was primarily due to the slightly lower average net sales price per unit and the higher average cost per unit sold, which was related to the mix of products sold during the quarter ended June 30, 2007. Gross margin will continue to be affected by the relative mix of products sold and changes in product sales price and costs that may occur.
Selling, General & Administrative
     Selling, general and administrative (SG&A) expense for the quarter ended June 30, 2007 decreased to approximately $6.3 million from approximately $7.6 million in the quarter ended June 30, 2006. Litigation expense related to the product liability lawsuits was approximately $830,000 (including the recognition of $100,000 for expected insurance reimbursement) for the quarter ended June 30, 2007, compared to approximately $2.1 million for product liability litigation expense in the quarter ended June 30, 2006.
     The lower SG&A expense is primarily due to the lower litigation expense as well as a decrease of $330,000 in legal expense incurred in the quarter ending June 30, 2006 associated with the Federal Trade Commission (FTC) inquiry initiated in early 2006, which has since been closed with no adverse findings. During the quarter ended June 30, 2007, we determined that our allowance for bad debt exceeded the amount of loss that would be likely and we reduced the allowance amount by approximately $250,000, which reduced SG&A expenses by an equal amount. In addition, there was approximately $600,000 of expense incurred in the quarter ended June 30, 2006 associated with the charitable donation of short-dated products.
     Offsetting the decrease in SG&A expense was an increase in selling expense of approximately $296,000, which is due to an increase in internal personnel and a change to the fee structure for some of our contract sales personnel.

14


Table of Contents

We expect selling expense for the entire fiscal year 2008 to be between 4% to 5% of net sales. In addition, there was a $350,000 increase in overall marketing expense wthat was primarily related to market and consumer research expense associated with the development of our oral care product.
     We expect SG&A expenses in future periods will vary largely in relation to the level of our advertising and legal expenditures. Advertising expense is heaviest during the cold season, which occurs October through March. We anticipate that we will continue to incur approximately $1.0 million in legal expense each quarter as a result of the Zicam Cold Remedy product liability litigation matters in which we are engaged (see Note 7 to the Condensed Consolidated Financial Statements).
Research and Development
     Research and development expense was approximately $1.5 million in the quarter ended June 30, 2007, approximately $400,000 less than the level incurred in the quarter ended June 30, 2006. We expect to invest 4% — 5% of fiscal 2008 annual net sales on research and development efforts. The increased research and development spending reflects the scale-up costs related to new products and our goal of continuing to expand the business by developing products in the oral care, antacid, and other categories. The timing of research and development spending can vary throughout the year and is not generally associated with our seasonal sales patterns.
Interest & Other Income
     Interest and other income was approximately $247,000 in the quarter ended June 30, 2007 versus approximately $135,000 in the quarter ended June 30, 2006. The increase in interest income is associated with our increased cash balances. Interest income in future periods will vary based on our level of cash and changes in interest rates.
Loss Before Benefit from Income Taxes
     Loss before income tax for the three months ended June 30, 2007 was approximately $(1.7) million, compared to approximately $(3.5) million for the quarter ended June 30, 2006. The reduced loss is primarily due to decreased SG&A expenses discussed above. We expect that net income in future periods will be significantly impacted by the sales levels of our products (including new products introduced in fiscal 2008), product introductions in new categories, and annual changes in our advertising, research and development, and legal expenses. We anticipate quarterly earnings will continue to vary along with the seasonality of sales.
Benefit for Income Taxes
     We recorded income tax benefit at our combined estimated annual effective tax rate of approximately 39%. Due to the reduced operating loss recorded in the quarter ended June 30, 2007, we recognized an income tax benefit of approximately $663,000 compared to a benefit of $1.6 million in the quarter ended June 30, 2006.
Net Loss
     Net loss was approximately $(1.1) million in the quarter ended June 30, 2007 compared to a net loss of approximately $(1.9) million in the quarter ended June 30, 2006.
Off-Balance Sheet Arrangements
     As of June 30, 2007, we did not have any off-balance sheet arrangements.
Liquidity and Capital Resources
     Our working capital was $38.6 million as of June 30, 2007, which was largely unchanged from March 31, 2007. During the first three months of fiscal 2008, we experienced a decrease in available cash of approximately $1.4 million. The decrease is primarily due to the seasonal increase in inventory and prepaid expenses as we prepare for the upcoming cold season.
     During the quarter ended June 30, 2007 trade receivables decreased to $6.2 million from $8.3 million on March 31, 2007. The decrease in accounts receivable relates to the collection of receivables that were generated during the transition quarter ended March 31, 2007 and the seasonally low sales we realized during the quarter ended June 30, 2007. We expect the receivables balance to increase as retailers begin preparing for the upcoming cold season.

15


Table of Contents

     The Company’s principal source of liquidity is cash generated from sales of our products to retailers and distributors. The majority of sales are given 30 day credit terms; however, payment terms are occasionally extended, as retailers begin to increase inventory of our products prior to the onset of the cough and cold season. The Company records an estimated allowance for potentially uncollectible accounts, which is reviewed on a monthly basis. During our recent review, we determined that our allowance for bad debt exceeded the amount of loss that would be likely and we reduced the allowance amount by approximately $250,000. This reduction is reflected in selling, general and administrative expenses. We believe our allowance as of June 30, 2007 is appropriate.
     The change in accounts receivable, inventory, accounts payable and accrued expenses largely reflects the increase in the Company’s business and reflects the seasonal nature of the Company’s business. Our working capital requirements fluctuate with the seasonality of our sales and are generally highest in the July through September quarter. The Company records the bulk of its sales, which is reflected in higher accounts receivable, in the second, third, and fourth fiscal quarters; generally builds inventory during the first through third fiscal quarter periods; and advertises its products, which is the largest component of accrued expenses, primarily in the third and fourth fiscal quarters. Although affected by the build-up of inventory, accounts payable and accrued expenses are more significantly affected by advertising spending, which primarily occurs in the third and fourth fiscal quarters.
     Generally, to the extent our operations are profitable, our business is cash-flow positive. We do have working capital requirements arising from the increase of inventory and accounts receivable in excess of the increase in accounts payable, but these vary throughout the year reflecting the seasonal nature of our business.
     Historically, the Company has had very low capital expenditures since we rely on contract manufacturers to produce our products. Typical capital expenditures include investments in technology, office furniture, leasehold improvements, and small tooling requirements. However, during calendar 2006 the Company spent approximately $4.2 million for an automated manufacturing line that is presently producing our swab products. The Company occasionally provides deposits and prepayments to our manufacturers to improve and increase manufacturing capabilities for our products. During the rest of fiscal 2008, the Company expects to invest approximately $400,000 in additional equipment for our new research and development facility.
     See Note 6 to the Condensed Consolidated Financial Statements for a discussion of our insurance program.
     We have an $8.0 million credit facility with Comerica Bank that was renewed July 2, 2007, until July 2009. The interest rate under the renewed credit facility is 0.25% below prime (or 8.0% at June 30, 2007), which represents a reduction from the previous rate of 0.25% above prime. In July 2006, we borrowed $4 million under the facility to support our working capital requirements in the third calendar quarter of 2006. We repaid the debt in the quarter ended December 31, 2006. We do not anticipate any borrowings from the credit facility for working capital needs during the next quarter. We are in compliance with the earnings and financial covenants contained in the credit facility.
Contractual Obligations
     We have entered into certain long-term contractual obligations that will require various payments over future periods as follows:
                                         
    Contractual Cash Obligations  
    (In thousands of dollars)  
    Payments due by Period as of June 30, 2007  
            Less than                     After  
    Total     1 year     1-3 years     3-5 years     5 years  
Long-Term Debt Obligations
  $ 0     $ 0     $ 0     $ 0     $ 0  
Capital Lease Obligations
    0       0       0       0       0  
Operating Lease Obligations
    550       137       315       98       0  
Purchase Obligations
    3,178       3,178       0       0       0  
Other Long-Term Liabilities Reflected on the Company’s Balance Sheet under GAAP
    0       0       0       0       0  
 
                             
Total
  $ 3,728     $ 3,315     $ 315     $ 98     $ 0  
 
                             

16


Table of Contents

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Forward Looking Statements
     This Report on Form 10-Q, including documents incorporated herein by reference, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “estimate,” “anticipate,” “intend,” “may,” “might,” “will,” “would,” “could,” “project” and “predict,” or similar words and phrases generally identify forward-looking statements. Forward looking statements contained herein and in documents incorporated by reference herein include, but are not limited to statements regarding:
    Our belief that the reserve for litigation losses will be sufficient to resolve the remaining product liability cases, exclusive of legal fees;
 
    our expectation of introducing new products during the 2007/2008 cold season;
 
    our expectations regarding fiscal 2008 net sales increasing 5%-15% over the $97.6 million recorded in the trailing twelve months ended March 31, 2007, and net income increasing to the range of $9.3 million to $10.8 million, compared to $6.5 million for the twelve months ended March 31, 2007;
 
    our belief that new advertising approaches and public relations efforts will continue to build brand awareness;
 
    our anticipation that we will continue to incur approximately $1.0 million in legal expense each quarter as a result of the Zicam Cold Remedy product liability and securities litigation in which we are engaged;
 
    our intention to vigorously defend the Zicam Cold Remedy product liability and securities litigation claims, our expectation that additional product liability lawsuits may be filed against us, and our belief that any liability resulting from these or other lawsuits, including any adverse publicity, could materially impact our financial results;
 
    our expectation that the trend of growth in sales in future periods will continue as we expand consumer awareness and acceptance of our entire Zicam brand of products, increase distribution, introduce new products, and avoid additional adverse publicity;
 
    our expectation regarding future net income, our belief that expenditures for advertising and research and development will vary by quarter throughout the year, and our expectation that advertising expenses will be heaviest in our third and fourth fiscal quarters;
 
    our expectation of the effect of recently issued accounting standards;
 
    our expectation that our mix of products sold will change due to seasonality and varying growth rates within our four market categories;
 
    our expectation of our 10 largest retailers adding new products;
 
    our expectation of future stock-based compensation;
 
    our expectations regarding seasonality of sales and earnings;
 
    our expectation of higher accounts receivable balances during the cold season;
 
    our belief that working capital requirements will not require any borrowings in the next quarter;
 
    our expectation of continuing profitability in future years;
 
    our intention to review our product return reserve provision monthly and adjust the reserve amounts as actual product return experience continues to develop;

17


Table of Contents

    our expectation of making income tax payments at our statutory rates in future years;
 
    our expectation that the average unit cost of goods sold and gross margin will continue to be affected by the relative mix of products sold;
 
    our expectation that our net income and operating expenses in future periods will vary largely in connection with the level of our advertising, research and development, and legal expenses;
 
    our expectation that research and development spending will be 4% to 5% of annual net sales in subsequent years;
 
    our expectation regarding dividends and retained earnings;
 
    our expectation of utilizing our tax loss carryforward;
 
    our expectation regarding investments in equipment;
 
    our expectation of recognizing additional charges related to stock options;
 
    our expectation that earnings in future periods will be significantly impacted by the seasonality of our sales, the severity of the cold season, the revenues and expenses associated with new products, and the timing and amount of advertising, research and development, and legal expenses;
 
    our belief that our existing capital resources and our credit line will be sufficient to fund our operations and capital requirements for the next 12 months;
 
    our expectation regarding reimbursement for legal expense from our insurance carriers;
 
    our having no plans to directly manufacture and store our products;
 
    our expectation that our manufacturers will have produced inventory available for sales of products through the 2007/2008 cough and cold season;
 
    our expectation of achieving a higher gross margin in the future; and
 
    our belief that moderate interest rate increases will not have a material adverse impact on our results of operations or financial position in the foreseeable future.
     We may make additional written or oral forward-looking statements from time to time in filings with the Securities and Exchange Commission or in public news releases. Such additional statements may include, but not be limited to, projections of revenues, income or loss, capital expenditures, acquisitions, plans for future operations, financing needs or plans, the impact of inflation and plans relating to our products or services, as well as assumptions relating to the foregoing. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying our forward-looking statements.
     Statements in this Report on Form 10-Q, including those set forth in the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and “Risk Factors,” describe factors that could contribute to or cause actual results to differ materially from our expectations. Other such factors include (i) less than anticipated demand for our current and future products, (ii) a weak cough and cold season, (iii) lack of market acceptance for or uncertainties concerning the efficacy or safety of our current and future products or regulatory actions involving our products, (iv) difficulties in increasing production or maintaining sufficient inventories to meet unexpectedly high demand in the short term, (v) financial difficulties encountered by one or more of our principal customers, (vi) difficulties in obtaining additional capital for marketing, research and development, and other expenses, (vii) material litigation involving patent and contractual claims, product liability claims, consumer issues and securities violation claims, (viii) the possibility of delays or other difficulties in implementing new product improvements and introducing to the marketplace new products and brands, (ix) the possibility that future sales of our products will not be as strong as expected, and (x) adverse publicity regarding our products or advertising restrictions.

18


Table of Contents

     Forward-looking statements contained in this Report on Form 10-Q speak only as of the date of this Report on Form 10-Q or, in the case of any document incorporated by reference, the date of that document. We do not undertake, and we specifically disclaim any obligation, to publicly update or revise any forward-looking statement contained in this Report on Form 10-Q or in any document incorporated herein by reference to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
     Our primary market risk exposure relates to our variable rate revolving line of credit with Comerica Bank. At no time during the first three months of fiscal 2008 did we have any outstanding balance against this line of credit. In July 2006, we borrowed $4 million against our credit facility with Comerica Bank. The primary purpose for the borrowing was to provide additional liquidity as we built inventory for expected increases in sales during the second half of calendar 2006. We fully repaid the debt in the fourth calendar quarter of 2006. Consequently, we believe that moderate interest rate increases will not have a material adverse impact on our results of operations or financial position in the foreseeable future. We generally extend payment terms for customers during the fiscal second quarter (calendar Q3) as customers purchase new products and build inventory for the upcoming cough and cold season.
     As of March 31, 2007 and June 30, 2007, we did not participate in any market risk-sensitive commodity instruments for which fair value disclosure would be required under Statement of Financial Accounting Standards No. 107. We believe that we are not subject in any material way to other forms of market risk, such as foreign currency exchange risk or foreign customer purchases (of which there were none in fiscal 2006, 2007, or the three month period ended June 30, 2007) or commodity price risk.
Item 4. Controls and Procedures
     We carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15 and 15d-15 of the Securities Exchange Act of 1934. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. There have been no changes in our internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) that occurred during the fiscal quarter ended June 30, 2007 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

19


Table of Contents

PART II
OTHER INFORMATION
Item 1. Legal Proceedings
     See Note 7 of the Condensed Consolidated Financial Statements for a discussion of the principal legal proceedings to which the Company is a party.
Item 1A. Risk Factors
     In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Transition Report on Form 10-KT for the period ended March 31, 2007, which could materially affect the business, financial condition or future results of the Company. The risks described in the transition period Form 10-KT are not the only risks facing the Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect the business, financial condition and/or operating results of the Company.
Item 4. Submission of Matters to a Vote of Security Holders
     At our 2007 annual meeting of stockholders held on May 15, 2007, our stockholders elected John M. Clayton, PhD., William C. Egan, and Michael A. Zeher to our Board of Directors for three-year terms each. There were present at the meeting, in person or by proxy, stockholders of the Company who were holders of record on the record date, of 8,673,939 shares of common stock, or 86% of the total shares of the outstanding common stock of the Company, which constituted a quorum. Of the 10,078,153 shares entitled to vote in such election, the votes cast were as follows:
                                 
Director   Votes For   Votes Withheld   Abstentions   Broker Non-Votes
John M. Clayton PhD.
    8,673,939       110,211       0       0  
William C. Egan
    8,673,449       110,701       0       0  
Michael A. Zeher
    8,673,039       111,111       0       0  
     At the time of the annual meeting, the Company’s five other directors Lori H. Bush, Samuel C. Cowley, Edward E. Faber, Carl J. Johnson, and L. White Matthews, III were not scheduled for election and will continue as members of the board.
     Additionally, stockholders ratified the anticipated appointment of Mayer Hoffman McCann P.C. as the independent registered public accounting firm of Matrixx Initiatives, Inc. for the fiscal year ending March 31, 2008. Of the 9,816,482 shares entitled to vote, the votes cast were as follows:
                         
Votes For   Votes Against   Abstentions   Broker Non-Votes
8,728,325
    44,939       10,886       0  

20


Table of Contents

Item 6. Exhibits
     
Exhibit No.   Title
 
   
3.01
  Articles of Incorporation and Amendments thereto of the registrant (1)
 
   
3.02
  Bylaws of the registrant (2)
 
   
4.01
  Rights Agreement dated as of July 22, 2002 by and between the registrant and Corporate Stock Transfer, Inc. (3)
 
   
10.01
  *Amendment Number Two to Amended and Restated Credit Agreement dated June 27, 2007 among the Registrant, Zicam, LLC and Comerica Bank
 
   
10.02
  *Replacement Secured Promissary Note dated June 27, 2007 among the Registrant, Zicam, LLC and Comerica Bank
 
   
10.03
  *Security Agreement dated July 5, 2007 among the Registrant, Matrixx Oral Care, LLC and Comerica Bank
 
   
10.04
  *Amendment Number One dated as of March 9, 2006 to the Amended and Restated Credit Agreement, dated as of September 27, 2005 by and among Matrixx Initiatives, Inc., Zicam, LLC and Comerica Bank
 
   
10.05
  * **Form of Change of Control Agreement
 
   
31.1*
  Certification of CEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
   
31.2*
  Certification of CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
   
32.1*
  Certification of CEO pursuant to 18 U.S.C. Section 1350
 
   
32.2*
  Certification of CFO pursuant to 18 U.S.C. Section 1350
 
*   Filed with this Report on Form 10-Q.
 
**   Indicates management compensatory contract, plan or arrangement.
 
(1)   Incorporated by reference to the Registrant’s Amendment No. 1 to Form 8-A, filed June 18, 2002, file number 000-27646.
 
(2)   Incorporated by reference to the Registrant’s Report on Form 8-K, filed July 25, 2006, file number 001-31404.
 
(3)   Incorporated by reference to the Registrant’s Registration Statement on Form 8-A, filed July 23, 2002, file number 001-31404.

21


Table of Contents

SIGNATURES
          In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
         
 
  Matrixx Initiatives, Inc.    
 
 
  /s/ Carl J. Johnson
 
Carl J. Johnson
   
 
  President and    
 
  Chief Executive Officer    
 
  August, 8, 2007    
 
       
 
  /s/ William J. Hemelt
 
William J. Hemelt
   
 
  Executive Vice President and    
 
  Chief Financial Officer    
 
  August 8, 2007    

22

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki